Wednesday, September 13, 2023
Shanghai Henlius Biotech has entered into an exclusive licencing agreement with PT Kalbe Genexine Biologics (KGbio) for the development and commercialisation of HANSIZHUANG, a serplulimab injection, targeting two indications, including extensive-stage small cell lung cancer (ES-SCLC).
HANSIZHUANG is the first and only anti-PD-1 therapy that has received approval for use in the first-line treatment of small cell lung cancer. Through KGbio's extensive commercial network and operational capabilities in the MENA (Middle East and North Africa) region, HANSIZHUANG will bring new era of hope and improved health for patients in both Southeast Asia and MENA.
This collaboration spans 12 Middle East and North African (MENA) countries, such as Saudi Arabia, the United Arab Emirates, Egypt, Qatar, Jordan, Morocco, etc.
Under the terms of the agreement, Henlius will undertake the responsibilities of manufacturing and supplying "HANSIZHUANG”. Henlius will initially receive a substantial upfront payment amounting to US$7 million. In addition to the upfront payment, Henlius has the opportunity to earn up to US$8 million contingent upon reaching regulatory milestones. These milestones are typically related to obtaining regulatory approvals and fulfilling regulatory requirements.
The agreement offers Henlius the potential to earn a substantial sum of up to US$650 million. These sales milestones extend beyond the MENA territory, encompassing 22 licenced countries in Southeast Asia and MENA.
